NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and Research News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and producti...
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery News Summary: Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to build autonomous lab infrastructure for scalable scientific discovery.Chai Discovery, Basecamp Research, Boltz and ecosystem leaders connect NVIDIA BioNeMo, agentic AI and physical AI to scale science and drug discovery. SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- J.P. Morgan Healthcare Conference -- NVIDIA today announced a major expansion of ™, an ope...
A director at NVIDIA Corp sold 200,000 shares at 187.818USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.